June 27 is National HIV Testing Day, a time to encourage people to learn their status. Early HIV diagnosis is critical, ...

The biggest barrier for those with HIV getting the care they need is not knowing they need it. In response, DAP Health is ...

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

The Trump administration's plan to cut funding for HIV vaccine research comes at a time when the field is making substantial ...

The Division of Public Health and Community Services is offering Human Immunodeficiency Virus testing in Nashua and Milford ...

Drawing from 19 studies across sub-Saharan Africa and select global contexts, the review finds that RHIS remain largely ...

In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be HIV-negative to get it.

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

The FDA approved lenacapavir (Yeztugo) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in at ...